Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.

Sewell H, Tanaka T, El Omari K, Mancini EJ, Cruz A, Fernandez-Fuentes N, Chambers J, Rabbitts TH.

Sci Rep. 2014 Jan 10;4:3643. doi: 10.1038/srep03643.

2.

Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex.

El Omari K, Hoosdally SJ, Tuladhar K, Karia D, Vyas P, Patient R, Porcher C, Mancini EJ.

Blood. 2011 Feb 17;117(7):2146-56. doi: 10.1182/blood-2010-07-293357. Epub 2010 Nov 12.

3.

Solution structure of a tethered Lmo2(LIM2) /Ldb1(LID) complex.

Dastmalchi S, Wilkinson-White L, Kwan AH, Gamsjaeger R, Mackay JP, Matthews JM.

Protein Sci. 2012 Nov;21(11):1768-74. doi: 10.1002/pro.2153. Epub 2012 Sep 25.

4.

Purification, crystallization and preliminary X-ray analysis of a fusion of the LIM domains of LMO2 and the LID domain of Ldb1.

El Omari K, Porcher C, Mancini EJ.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Nov 1;66(Pt 11):1466-9. doi: 10.1107/S1744309110032872. Epub 2010 Oct 28.

5.

LMO2 at 25 years: a paradigm of chromosomal translocation proteins.

Chambers J, Rabbitts TH.

Open Biol. 2015 Jun;5(6):150062. doi: 10.1098/rsob.150062. Review.

6.

LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.

Layer JH, Alford CE, McDonald WH, Davé UP.

Mol Cell Biol. 2015 Nov 23;36(3):488-506. doi: 10.1128/MCB.00901-15.

7.

The LMO2 -25 Region Harbours GATA2-Dependent Myeloid Enhancer and RUNX-Dependent T-Lymphoid Repressor Activity.

Bonadies N, Göttgens B, Calero-Nieto FJ.

PLoS One. 2015 Jul 10;10(7):e0131577. doi: 10.1371/journal.pone.0131577. eCollection 2015.

8.

Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene.

Venkitachalam S, Chueh FY, Yu CL.

Biochem Biophys Res Commun. 2012 Jan 20;417(3):1058-62. doi: 10.1016/j.bbrc.2011.12.095. Epub 2011 Dec 27.

9.

An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions.

Nam CH, Lobato MN, Appert A, Drynan LF, Tanaka T, Rabbitts TH.

Oncogene. 2008 Aug 21;27(36):4962-8. doi: 10.1038/onc.2008.130. Epub 2008 Apr 28.

PMID:
18438427
10.

Chromosomal translocations and leukaemia: a role for LMO2 in T cell acute leukaemia, in transcription and in erythropoiesis.

Rabbitts TH, Axelson H, Forster A, Grutz G, Lavenir I, Larson R, Osada H, Valge-Archer V, Wadman I, Warren A.

Leukemia. 1997 Apr;11 Suppl 3:271-2.

PMID:
9209362
11.

HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias.

Calero-Nieto FJ, Joshi A, Bonadies N, Kinston S, Chan WI, Gudgin E, Pridans C, Landry JR, Kikuchi J, Huntly BJ, Gottgens B.

Oncogene. 2013 Nov 28;32(48):5471-80. doi: 10.1038/onc.2013.175. Epub 2013 May 27.

12.

A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.

Oram SH, Thoms JA, Pridans C, Janes ME, Kinston SJ, Anand S, Landry JR, Lock RB, Jayaraman PS, Huntly BJ, Pimanda JE, Göttgens B.

Oncogene. 2010 Oct 28;29(43):5796-808. doi: 10.1038/onc.2010.320. Epub 2010 Aug 2.

PMID:
20676125
13.

The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.

Yamada Y, Pannell R, Forster A, Rabbitts TH.

Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):320-4.

14.

LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.

Cerhan JR, Natkunam Y, Morton LM, Maurer MJ, Asmann Y, Habermann TM, Vasef MA, Cozen W, Lynch CF, Allmer C, Slager SL, Lossos IS, Chanock SJ, Rothman N, Hartge P, Dogan A, Wang SS.

Leuk Lymphoma. 2012 Jun;53(6):1105-12. doi: 10.3109/10428194.2011.638717. Epub 2012 Jan 3.

15.

Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells.

Deleuze V, El-Hajj R, Chalhoub E, Dohet C, Pinet V, Couttet P, Mathieu D.

PLoS One. 2012;7(7):e40484. doi: 10.1371/journal.pone.0040484. Epub 2012 Jul 6.

16.

Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.

Goodings C, Tripathi R, Cleveland SM, Elliott N, Guo Y, Shyr Y, Davé UP.

Leuk Res. 2015 Jan;39(1):100-9. doi: 10.1016/j.leukres.2014.11.016. Epub 2014 Nov 29.

17.

LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype.

Patel JL, Pournazari P, Haggstrom SJ, Kosari F, Shabani-Rad MT, Natkunam Y, Mansoor A.

Histopathology. 2014 Jan;64(2):226-33. doi: 10.1111/his.12242. Epub 2013 Nov 6.

PMID:
24330148
18.

Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.

McCormack MP, Shields BJ, Jackson JT, Nasa C, Shi W, Slater NJ, Tremblay CS, Rabbitts TH, Curtis DJ.

Blood. 2013 Sep 19;122(12):2093-103. doi: 10.1182/blood-2012-09-458570. Epub 2013 Aug 7.

19.

LIM-only protein Lmo2 forms a protein complex with erythroid transcription factor GATA-1.

Osada H, Grutz GG, Axelson H, Forster A, Rabbitts TH.

Leukemia. 1997 Apr;11 Suppl 3:307-12.

PMID:
9209374
20.

Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.

Appert A, Nam CH, Lobato N, Priego E, Miguel RN, Blundell T, Drynan L, Sewell H, Tanaka T, Rabbitts T.

Cancer Res. 2009 Jun 1;69(11):4784-90. doi: 10.1158/0008-5472.CAN-08-4774.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk